Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Search
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
EFPIA disclosure
Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs